Skip to main content
Figure 2 | BMC Nephrology

Figure 2

From: Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study

Figure 2

LS mean percentage change in eGFR. (A) Change from baseline over time (full analysis population). Last-observation-carried-forward principle was applied to missing values of continuous variables. eGFR = estimated glomerular filtration rate; LS = least squares; EOT = end of treatment; EOF = end of follow-up. (B) Change from baseline over time, by eGFR strata (full analysis population). Last-observation-carried-forward principle was applied to missing values of continuous variables.

Back to article page